TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29315019
Drug: Daily almond
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily almond intake (56 g per day for 20 weeks)
Study: 15327724
Drug: Imitative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imitative treatment
Study: 9335367
Drug: Heparin-coated cardiopulmonary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated cardiopulmonary bypass system
Study: 24240061
Drug: Therapeutic exercise
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic exercise with ultrasound and microcurrent therapy
Study: 16679823
Drug: Glycerol-based hydration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol-based hydration cream
Study: 8817007
Drug: Ambulatory blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambulatory blood pressure (ABP) group, lisinopril 10 mg/day, could be adjusted to 10 or 20 mg/day or discontinued after one month based on blood pressure levels.
Study: 8817007
Drug: Conventional blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional blood pressure (CBP) group, lisinopril 10 mg/day, could be adjusted to 10 or 20 mg/day or discontinued after one month based on blood pressure levels.
Study: 31663816
Drug: Anabolic androgen
Normalized name: Anabolic androgenic steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anabolic androgen steroids (AS) users
Study: 631039
Drug: Both oral
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both oral Ro 10-9359 and local dithranol application
Study: 31766250
Drug: Low-dose iron
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose iron MNP (5.0 mg iron)
Study: 28947039
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate 100 μg (FF)
Study: 26520227
Drug: Mindfulness Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness Therapy for Maladaptive Interpersonal Dependency (MT‐MID)
Study: 16317312
Drug: Risperidone (4.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (4.6 mg/day mean dose)
Study: 16432076
Drug: Interferon (IFN)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN) maintenance therapy
Study: 9313875
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy package including IFN
Study: 8313405
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg of nifedipine (Group II)
Study: 23849436
Drug: Fasting state
Normalized name: CLOZAPINE (GOLDEN STATE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting state (clinofibrate 400 mg)
Study: 23849436
Drug: Fed state
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fed state (clinofibrate 400 mg)
Study: 21181364
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment plus simvastatin (group R+S)
Study: 21181364
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (group R)
Study: 17428528
Drug: Dexamphetamine (10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamphetamine (10mg daily for 5 days)
Study: 10343626
Drug: Inhaled Fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Fluticasone Propionate (FP)
Study: 10343626
Drug: Inhaled Triamcinolone
Normalized name: triamcinolone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Triamcinolone Acetonide (TAA)
Study: 10343626
Drug: Intranasal Fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal Fluticasone Propionate (FP)
Study: 8606898
Drug: Neurodevelopmental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurodevelopmental treatment (NDT) for 5 days
Study: 8606898
Drug: Treatment duration
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment duration (both types)
Study: 1945978
Drug: Regimen A
Normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A (chloral hydrate 50 mg/kg + hydroxyzine pamoate 25 mg + meperidine 1.5 mg/kg)
Study: 7047580
Drug: Buprenorphine (0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (0.3, 0.45, or 0.6 mg)
Study: 20137767
Drug: Tramadol Contramid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol Contramid OAD 200 mg tablets
Study: 20137767
Drug: Monocrixo L.P.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monocrixo L.P. 200 mg capsules
Study: 8295245
Drug: Clotrimazole 10
Normalized name: clotrimazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole 10 mg three times a day
Study: 14551182
Drug: Ketoconazole 200
Normalized name: ketoconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 200 mg per day
Study: 3389331
Drug: Medium-chain triglycerides
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-chain triglycerides (MCT) at doses of 100, 200, and 300 kcal
Study: 30572528
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl patch (TFP) 25 μg/h
Study: 20954214
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of ondansetron (8 mg)
Study: 9262266
Drug: Modified suppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified suppression gonadotrophin-releasing hormone agonist protocol
Study: 8486173
Drug: 4 or
Normalized name: Dex4 Orange
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 or 8 mg of oral E2 and vaginal ultrasound (US) daily until endometrial thickness > or = 6 mm with a triple‐line pattern
Study: 2547137
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of hormone therapy
Study: 27449404
Drug: Ramosetron (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron (0.3 mg)
Study: 23313969
Drug: Ramosetron plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron plus Dexamethasone (8 mg + 0.3 mg)
Study: 16761228
Drug: Tiotropium bromide
Normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiotropium bromide 18 microg once daily
Study: 9200849
Drug: TMB exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMB exposure and its metabolites in biological fluids.
Study: 2888658
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg mifentidine
Study: 26256990
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (ventilation with a tidal volume of 8 mL/kg)
Study: 26256990
Drug: PEEP group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEEP group (ventilation with a tidal volume of 6 mL/kg and PEEP of 8 cm H₂O)
Study: 16781225
Drug: Trimetazidine (TMZ)
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (TMZ) 40 mg TID
Study: 9737645
Drug: Cerivastatin 0.4
Normalized name: cerivastatin 0.4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin 0.4 mg/day
Study: 9737643
Drug: Cerivastatin 0.2
Normalized name: cerivastatin 0.2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin 0.2 mg/day
Study: 1207435
Drug: Caffeine (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (7 mg/kg)
Study: 6131448
Drug: Crotylbarbital (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crotylbarbital (2 mg/kg)
Study: 30782716
Drug: Automated oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated oxygen administration (FreeO2 group)
Study: 30782716
Drug: Conventional oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oxygen therapy (Standard group)
Study: 26773108
Drug: Brodalumab 280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brodalumab 280 mg
Study: 19902267
Drug: Combination steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination steroid and mizoribine (MZB) therapy (4-5 mg/kg/day)
Study: 19902267
Drug: Steroid only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid only therapy
Study: 30736770
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (n = 25)
Study: 26645159
Drug: Ultrasound-guided injection
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided injection (USGI) of corticosteroids (20mg of methylprednisolone acetate)
Study: 26645159
Drug: Conventional blind
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional blind injection (CBI) of corticosteroids (20mg of methylprednisolone acetate)
Study: 17920731
Drug: HIV‐1 DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV‐1 DNA vaccine
Study: 16132246
Drug: Dietary therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary therapy alone (control group)
Study: 11881315
Drug: Ibuprofen (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (400 mg) administered orally 12 and 2 hours before surgery, and every 8 hours until the third postoperative day.
Study: 11881315
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no ibuprofen treatment).
Study: 10225548
Drug: Sanguinarine toothpaste
Normalized name: sanguinarine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sanguinarine toothpaste and oral rinse
Study: 10225548
Drug: Control toothpaste
Normalized name: Sodium Fluoride Dental Paste [TARTAR CONTROL TOOTHPASTE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control toothpaste and oral rinse without sanguinarine
Study: 8942892
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (0.5 mg/ml)
Study: 27920416
Drug: Intravenous pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pantoprazole 40 mg daily
Study: 26905705
Drug: Mifepristone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (200 mg) followed by vaginal misoprostol induction
Study: 22160450
Drug: Both meals
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both meals (olive oil and cream)
Study: 9864279
Drug: 21 mg/day
Normalized name: nicotine 21 MG/Day 24HR Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 mg/day transdermal nicotine
Study: 9864279
Drug: 42 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 42 mg/day transdermal nicotine
Study: 9864279
Drug: 63 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 63 mg/day transdermal nicotine
Study: 8748047
Drug: lorazepam (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: lorazepam (mean daily dose 4.2 mg)
Study: 6118384
Drug: Prazosin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (2 mg nebulized)
Study: 28004320
Drug: Adjunctive brivaracetam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive brivaracetam
Study: 19274788
Drug: Intravenous fluid
Normalized name: Intravenous fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluid
Study: 10546710
Drug: Inpatient therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient therapy
Study: 2512936
Drug: Intensive outpatient
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive outpatient therapy
Study: 29512795
Drug: Inhaled nitrous
Normalized name: nitrous oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitrous oxide (MEOPA)
Study: 15111138
Drug: High frequency
Normalized name: ALCOHOL 0.7 mL in 1 mL TOPICAL SOLUTION [enMotion Foam High Frequency Use]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High frequency exercise program (twice daily, including weekends)
Study: 15111138
Drug: Low frequency
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low frequency exercise program (once daily, not on weekends)
Study: 9054253
Drug: High-dose mivazerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose mivazerol (1.5 micrograms.kg‐1.h‐1)
Study: 9054253
Drug: Low-dose mivazerol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose mivazerol (0.75 microgram.kg‐1.h‐1)
Study: 26385666
Drug: Standard fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard fluid therapy with supplementary intraoperative stroke volume optimization (mean 956 ml Gelofusine)
Study: 18054930
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen supplementation (100 microg/d)
Study: 18054930
Drug: No transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No transdermal estrogen supplementation
Study: 8818502
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for primary site recurrence
Study: 31280967
Drug: Adalimumab (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (40 mg)
Study: 31574261
Drug: 0.1-mL lavender
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1-mL lavender oil diffusion
Study: 26779620
Drug: Spirulina maxima
Normalized name: SPIRULINA MAXIMA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirulina maxima supplementation (2 g daily for 3 months)
Study: 22648340
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mild exercise, hyperventilation, and normobaric hyperoxia (100% oxygen inhalation)
Study: 16631880
Drug: bivalent HPV‐16/18
Approvals — FDA: no, EMA: no, PMDA: no
Description: bivalent HPV‐16/18 virus‐like particle AS04 vaccine
Study: 11083892
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for chylous effusions
Study: 1728708
Drug: Diclofenac, 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac, 75 mg intramuscularly twice daily
Study: 7878629
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg recombinant tissue plasminogen activator (t‐PA)
Study: 3071175
Drug: Preoperative continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative continuous nifedipine maintenance medication (10-20 mg p.o.)
Study: 3071175
Drug: Nifedipine morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine morning dose
Study: 3071175
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (last nifedipine medication evening before surgery)
Study: 28414485
Drug: Prolonged Exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged Exposure therapy with incentives (PE + I; max $480)
Study: 3489270
Drug: bepridil (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: bepridil (2 mg/kg)
Study: 31581523
Drug: Inositol-enhanced arginine
Normalized name: Inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inositol-enhanced arginine silicate oral supplement
Study: 26279065
Drug: 1.4 g
Normalized name: MENTHOL 1.4 g in 100 g TOPICAL CREAM [Cetilar]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.4 g day-1 omega-3 polyunsaturated fatty acids (PUFAs) plus cognitive-behavioural case management (CBCM)
Study: 23249829
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (ACE inhibitor ramipril + ARB telmisartan)
Study: 23249829
Drug: Monotherapy (either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (either ramipril or telmisartan)
Study: 23249829
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy vs. monotherapy
Study: 10966249
Drug: Iron group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron group (received 20 mg of iron saccharate intravenously daily for 14 days)
Study: 10966249
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (received no additional therapy)
Study: 8798250
Drug: Mean fasting
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean fasting insulin levels
Study: 1451070
Drug: Concurrent radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent radiation therapy (RT) with vinblastine
Study: 28705783
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral simethicone)
Study: 10210990
Drug: High titre
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High titre vaccine (10(3.9) and 10(4.0) pfu)
Study: 26214111
Drug: Focused education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focused education and medication management intervention
Study: 29775988
Drug: RT twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT twice a week (G2X)
Study: 26738606
Drug: Neoadjuvant TAC
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant TAC chemotherapy with zoledronic acid
Study: 26738606
Drug: Neoadjuvant TAC
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant TAC chemotherapy without zoledronic acid
Study: 10778587
Drug: Hartone 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hartone 2 caps twice daily for 6 weeks and 1 cap twice daily for the next 6 weeks
Study: 10778587
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate (ISMN) 20 mg twice daily
Study: 8176573
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy with corticotropin (ACTH) - 150 U/m2 per day for 3 weeks, 80 U/m2 per day for 2 weeks, 80 U/m2 every other day for 3 weeks, and 50 U/m2 per day every other day for 1 week, tapered to zero over 3 weeks.
Study: 8176573
Drug: Low-dose therapy
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose therapy with corticotropin (ACTH) - 20 to 30 U/day for 2 to 6 weeks, tapered to zero over 1 week.
Study: 2855105
Drug: Loperamide (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (16 mg orally) + LVP (0.06 IU/kg i.v. over 1 h)
Study: 2855105
Drug: Loperamide (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (16 mg orally) + Placebo + LVP (0.06 IU/kg i.v. over 1 h)
Study: 2855105
Drug: Loperamide (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (16 mg orally) + CRH (1 micrograms/kg i.v. as bolus)
Study: 23839175
Drug: Adapalene 0.1%-benzoyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene 0.1%-benzoyl peroxide 2.5% gel (adapalene-BPO)
Study: 18063500
Drug: glyburide 5
Normalized name: glyburide 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: glyburide 5 mg b.i.d.
Study: 9529028
Drug: Granulocyte‐macrophage‐colony stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte‐macrophage‐colony stimulating factor (GM‐CSF) at a dose of 10 microg/kg per day, administered subcutaneously, on a 14‐days‐on/14‐days‐off schedule
Study: 9529028
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) at a dose of 400 mg administered orally 4 times per day
Study: 7977546
Drug: Intravenous oxytocin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous oxytocin, 20 U
Study: 27174580
Drug: Premeal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premeal insulin
Study: 21144709
Drug: Oral piroxicam
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral piroxicam 20mg
Study: 18499605
Drug: Low-dose sevoflurane
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sevoflurane inhalation (0.5-1 vol % end-tidal concentration in oxygen 50 vol %)
Study: 12752022
Drug: Short cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short cognitive-behavioral group treatment
Study: 2715552
Drug: LY171883 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY171883 (400 mg)
Study: 324270
Drug: Methylcellulose (Celevac)
Normalized name: Methylcellulose
DrugBank: Methylcellulose (DB11228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylcellulose (Celevac) - two tablets daily
Study: 324270
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - two tablets daily
Study: 324270
Drug: Methylcellulose (Celevac)
Normalized name: Methylcellulose
DrugBank: Methylcellulose (DB11228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylcellulose (Celevac) - two tablets daily (crossover group)
Study: 23061994
Drug: Lidocaine gel
Normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine gel
Study: 24435717
Drug: Preventive medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive medication action at the time of an office visit
Study: 9809926
Drug: Carvedilol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (10 mg twice a day)
Study: 11268711
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg for 24 weeks
Study: 9822940
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg three times daily)
Study: 8130042
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine 20 ml